Epigenictx
Founded 2021 · 17 employees on LinkedIn · 2 known investors
Find your way into Epigenictx
Epigenic Therapeutics develops gene regulation-based biotherapeutics using its EPIREG platform, which applies AI algorithms to design CRISPR-Cas components that regulate target gene expression without altering the DNA sequence. Combined with a lipid nanoparticle delivery system, the technology targets metabolic, cardiovascular, viral hepatitis, ocular, oncology and rare diseases.
Founders & leadership
CY
Chloe YouinChief Medical Officer
KS
Kelly ShiChief Financial Officer
Investors · 2
Frequently asked questions
- What does Epigenictx do?
- Epigenic Therapeutics develops gene regulation-based biotherapeutics using its EPIREG platform, which applies AI algorithms to design CRISPR-Cas components that regulate target gene expression without altering the DNA sequence. Combined with a lipid nanoparticle delivery system, the technology targets metabolic, cardiovascular, viral hepatitis, ocular, oncology and rare diseases.
- Who are Epigenictx's investors?
- Epigenictx's investors include OrbiMed, Qiming Venture Partners.